Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation - Summary - DentalSpire

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • By

  • Kristina Maas-Bauer

  • Thomas Meyer

  • Mehtap Yücel

  • Maria Garofalaki

  • Stefanie Koßmann

  • Francesca Biavasco

  • Memnon Lysandrou

  • Miguel Waterhouse

  • Tobias Feuchtinger

  • Dietmar Pfeifer

  • Florian Ingelfinger

  • Tobias Wertheimer

  • Justus Duyster

  • Jae Sook Ahn

  • Robert J. Soiffer

  • Jürgen Finke

  • Ralph Wäsch

  • Alexandros Spyridonidis

  • Dennis Dong Hwan Kim

  • Claudia Wehr

  • Robert Zeiser

  • April 3, 2026

Share

Objective:

To evaluate the mutational dynamics of AML cells in patients who experienced relapse after allo-HCT and assess how these changes relate to clinical outcomes.

Approach:
    Key Findings:
    • 68% of patients exhibited genetic instability with acquisition or loss of mutations.
    • Frequent mutations involved FLT3-ITD, NRAS, and KRAS, while founding lesions like DNMT3A were retained.
    • Clonal evolution patterns included constant (35.0%), linear (29.8%), branching (22.8%), and parallel (12.3%) evolution.
    • Early relapse (≤ 6 months) significantly increased mortality risk compared to late relapse.
    Interpretation:

    Relapse after allo-HCT in AML is genetically diverse, with timing of relapse being the most critical factor influencing patient outcomes.

    Limitations:
    • The retrospective nature of the study may introduce bias in the findings.
    • The limited sample size may affect the generalizability of the results.
    Conclusion:

    Longitudinal molecular monitoring post-transplant is crucial for informing therapeutic options, especially given the observed genetic diversity in relapsed AML.

Original Source(s)

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • by Kristina Maas-Bauer, Thomas Meyer, Mehtap Yücel, Maria Garofalaki, Stefanie Koßmann, Francesca Biavasco, Memnon Lysandrou, Miguel Waterhouse, Tobias Feuchtinger, Dietmar Pfeifer, Florian Ingelfinger, Tobias Wertheimer, Justus Duyster, Jae Sook Ahn, Robert J. Soiffer, Jürgen Finke, Ralph Wäsch, Alexandros Spyridonidis, Dennis Dong Hwan Kim, Claudia Wehr, Robert Zeiser

  • April 3, 2026

Related Content

Virtual Staining and the Next Era of Pathology

How AI enables scalable biomarker analysis that preserves tissue samples, addressing some of the most persistent bottlenecks in clinical care and research

Correction: Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study)

The lactylation axis: bridging metabolic reprogramming and immunosuppression in the tumor microenvironment